{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-26-000029","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2026-08-06T20:18:50+00:00","discovered_at":"2026-08-06T20:20:01.347003+00:00","generated_at":"2026-08-06T20:20:52.639937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"vTv Therapeutics Q2 net loss $13.1M; Phase 3 T1D trial enrollment to complete Q3 2026","bullets":["Net loss of $13.1M ($1.05 per share) vs $6.0M loss ($0.92) in Q2 2025; R&D spend rose to $8.8M from $4.1M.","Cash and equivalents $86.6M at June 30, 2026; company expects runway through CATT1 topline data readout.","Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes expected to complete enrollment in Q3 2026.","Phase 2a Hybrid CATT1 trial (hybrid closed-loop) to initiate before year-end 2026; KOL event planned Q4 2026.","Six-month revenue of $36.8M (vs $0 in prior year) from a milestone; net income of $11.1M for H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-26-000029","json":"https://secwatch.observer/filing/0001641489-26-000029.json","markdown":"https://secwatch.observer/filing/0001641489-26-000029.md","text":"https://secwatch.observer/filing/0001641489-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/0001641489-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/vtvt-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:20:52.639937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}